Get started
Prothena Corporation plcProthena Corporation plcProthena Corporation plc

Prothena Corporation plc

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

PRTA chart


Full chart

PRTA upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪940.62 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.95 USD
Net income (FY)
‪−147.03 M‬ USD
Revenue (FY)
‪91.37 M‬ USD
Shares float
‪46.42 M‬
Beta (1Y)
0.78

Employees


Employees (FY)
173
Change (1Y)
+46 +36.22%
Revenue / Employee (1Y)
‪528.15 K‬ USD
Net income / Employee (1Y)
‪−849.87 K‬ USD

About Prothena Corporation plc


Sector
Health Technology
Industry
Biotechnology
CEO
Gene G. Kinney
Website
prothena.com
Headquarters
Dublin
Founded
2012
ISIN
IE00B91XRN20
FIGI
BBG003PDKJF7
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

PRTA news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of PRTA is 17.61 USD — it has decreased by −4.69% in the past 24 hours. Watch Prothena Corporation plc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Prothena Corporation plc stocks are traded under the ticker PRTA.
PRTA stock has fallen by −3.26% compared to the previous week, the month change is a 5.81% rise, over the last year Prothena Corporation plc has showed a −50.62% decrease.
We've gathered analysts' opinions on Prothena Corporation plc future price: according to them, PRTA price has a max estimate of 94.00 USD and a min estimate of 24.00 USD. Watch PRTA chart and read a more detailed Prothena Corporation plc stock forecast: see what analysts think of Prothena Corporation plc and suggest that you do with its stocks.
PRTA reached its all-time high on Sep 27, 2021 with the price of 79.75 USD, and its all-time low was 5.64 USD and was reached on Jan 18, 2013. View more price dynamics on PRTA chart.
See other stocks reaching their highest and lowest prices.
PRTA stock is 3.79% volatile and has beta coefficient of 0.78. Track Prothena Corporation plc stock price on the chart and check out the list of the most volatile stocks — is Prothena Corporation plc there?
Today Prothena Corporation plc has the market capitalization of ‪940.62 M‬, it has increased by 11.12% over the last week.
Yes, you can track Prothena Corporation plc financials in yearly and quarterly reports right on TradingView.
Prothena Corporation plc is going to release the next earnings report on Nov 12, 2024. Keep track of upcoming events with our Earnings Calendar.
PRTA earnings for the last quarter are 1.22 USD per share, whereas the estimation was −1.06 USD resulting in a 215.22% surprise. The estimated earnings for the next quarter are −1.18 USD per share. See more details about Prothena Corporation plc earnings.
Prothena Corporation plc revenue for the last quarter amounts to ‪132.01 M‬ USD, despite the estimated figure of ‪10.73 M‬ USD. In the next quarter, revenue is expected to reach ‪1.22 M‬ USD.
PRTA net income for the last quarter is ‪66.89 M‬ USD, while the quarter before that showed ‪−72.24 M‬ USD of net income which accounts for 192.59% change. Track more Prothena Corporation plc financial stats to get the full picture.
No, PRTA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2024, the company has 173.00 employees. See our rating of the largest employees — is Prothena Corporation plc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Prothena Corporation plc EBITDA is ‪−72.98 M‬ USD, and current EBITDA margin is −199.87%. See more stats in Prothena Corporation plc financial statements.
Like other stocks, PRTA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Prothena Corporation plc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Prothena Corporation plc technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Prothena Corporation plc stock shows the sell signal. See more of Prothena Corporation plc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.